Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

489 - Correlation between circulating tumor cells and the aromatase inhibitors therapy in postoperative patients with early breast cancer.

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Yumei Shi

Citation

Annals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426

Authors

Y. Shi, G. Zhang, Y. Wang, C. Ren, L. Wen, L. Guo, N. Liao

Author affiliations

  • Cancer Center, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 510080 - guangzhou/CN
More

Resources

Abstract 489

Background

To investigate the effects of non-steroidal aromatase inhibitors (NSAIs) on lipid metabolism and the correlation between NSAIs therapy and circulating tumor cells (CTCs) in postoperative patients with early-stage breast cancer.

Methods

We retrospectively analyzed 264 patients with early stage breast cancer (T1-3N0-3M0) in Guangdong General Hospital from 2009 to 2016. Patients with baseline lipid metabolism data were recruited in this study. The prevalence and number of CTCs were assessed using the CellSearch System at a mean time of 22.5 months after NSAIs therapy. Fasting blood was also drawn at the same time to assess lipid metabolism. We collected the clinical data, baseline metabolic-related data of all the recruited patients, and analyzed the lipid metabolism changes in patients received different NSAIs and the correlation between NSAIs therapy and CTC presence.

Results

We enrolled 90 patients with baseline lipid metabolism-related data, with an average follow-up of 22.5 months. There was no significant correlation between CTC presence and NSAIs therapy. However, LDL and Apolipoprotein B100 were significantly increased in letrozole group during follow-up (p = 0.004, p = 0.016). The levels of Apolipoprotein A1 in both anastrozole and letrozole groups were also significantly increased (p = 0.044, p = 0.034). No significant change was observed in the control group during follow-up.Table: 14P

Change in lipid indicators after 20 months of aromatase inhibitor therapy

Anatrozole Group (n = 25)Letrozole Group (n = 42)No endocrine therapy (n = 23)
LDL(mmol/l)
Baseline3.36±1.13.17±0.852.94±0.55
Follow-up3.41±0.880.053.47±0.830.3*3.2±0.790.26
TC(mmol/l)
Baseline5.53±0.995.24±1.185±0.74
Follow-up5.43±0.93-0.15.47±1.20.23*5.32±0.980.32
Apolipoprotein A1(g/l)
Baseline1.36±0.211.37±0.261.5±0.36
Follow-up1.42±0.130.06*1.46±0.220.11*1.43±0.24-0.07
Apolipoprotein B100(g/l)
Baseline10.90.89
Follow-up1010.1*0.90.01

Conclusions

There is no correlation between NSAIs therapy and CTC. Compared with anastrozole, letrozole has a more adverse long-term effect on lipid metabolism in patients.

Editorial acknowledgement

Clinical trial identification

The study was approved by the Institutional Review Board of Guangdong General Hospital (IRB NO. GDREC2012113H(R1)).

Legal entity responsible for the study

Guangdong General Hospital and Guangdong Academy of Medical Sciences.

Funding

The Special Fund of Development of Technology by Guangdong Province (No.2016A030313768), the National Natural Science Foundation of China (No. 81602645), the Science and Technology Project of Guangdong Province (No. 2012A03040001).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings